Shanghai S.E.
23:00:00 23/05/2024 BST
5-day change
1st Jan Change
3.88
CNY
-1.02%
-4.67%
-32.05%
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
October 30, 2020 at 09:55 am
Shanghai Fudan Forward S&T Co. Ltd. announced earnings results for the nine months ended September 30, 2020. For the nine months, the company announced sales was CNY 714.888 million compared to CNY 1,140.226 million a year ago. Operating income was CNY 52.263 million compared to CNY 69.477 million a year ago. Net income was CNY 24.692 million compared to CNY 42.431 million a year ago. Basic earnings per share from continuing operations was CNY 0.0361 compared to CNY 0.062 a year ago.
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
04-29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
04-29
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
27/10/23
CI
Fudan Forward S&T to Auction Office Property For At Least 31 Million Yuan
12/10/23
MT
Fudan Forward S&T Chairman Retires
29/09/23
MT
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
30/08/23
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
28/04/23
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
28/04/23
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
28/10/22
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
26/08/22
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
29/04/22
CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021.
31/03/22
CI
Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback announced on June 30, 2021, has expired with 5,365,068 shares, representing 0.78% for CNY 35.01 million.
29/03/22
CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021.
04/01/22
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
29/10/21
CI
Tranche Update on Shanghai Fudan Forward S&T Co., Ltd's Equity Buyback Plan announced on June 30, 2021.
08/10/21
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
27/08/21
CI
Shanghai Fudan Forward S&T Co., Ltd commences an Equity Buyback Plan for CNY 70 million worth of its shares, under the authorization approved on April 8, 2021.
29/06/21
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
29/04/21
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
29/04/21
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020
30/10/20
CI
Shanghai Fengxian Investment Co., Ltd. completed the acquisition of 10% stake in Shanghai Fudan Forward Pharmaceutical Co., Ltd. from Shanghai Fudan Forward S&T Co., Ltd
22/09/20
CI
Shanghai Fengxian Investment Co., Ltd., completed the acquisition of 18.74% stake in Shanghai Fudan Forward S&T Co., Ltd from Fudan University, Endowment Arm.
03/09/20
CI
Shanghai Fudan Forward S&T Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2020
21/08/20
CI
Shanghai Fudan Forward S&T Co., Ltd Announces Tax Included Final Cash Dividend for the Full Year of 2019, Payable on August 03, 2020
22/07/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SHANGHAI FUDAN FORWARD S&T CO., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's pharmaceuticals include digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, immune function medications and others. The Company is also engaged in the provision of financial insurance software products. It distributes its products within domestic markets and to overseas markets.
More about the company
1st Jan change
Capi.
-32.05% 364M +18.04% 42.95B +16.92% 21.38B +18.33% 15.05B +19.27% 14.45B +56.12% 13.04B -0.05% 6.79B -10.73% 6.72B -8.87% 5.73B +11.21% 5.47B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SHANGHAI FUDAN FORWARD S&T CO., LTD 
